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Clinical implementationPurpose: To report on the potential beneﬁts of swallowing-sparing intensity-modulated radiation ther-
apy (SW-IMRT) in the ﬁrst 100 SW-IMRT treated patients, as well as on the factors that inﬂuence the
potential beneﬁt of SW-IMRT relative to standard parotid sparing (ST)-IMRT.
Material and methods: One hundred consecutive head and neck cancer patients, scheduled for primary
radiotherapy, were included in this prospective cohort study. For each patient, ST-IMRT and SW-IMRT
treatment plans were created. All patients were eventually treated with SW-IMRT. Objectives for SW-
IMRT were identical to those with ST-IMRT, with additional objectives to spare the swallowing organs
at risk (SWOARs). After 20 patients, interim results were evaluated by a multidisciplinary committee.
Results: The mean gain of SW-IMRT relative to ST-IMRT in the ﬁrst 20 patients was less than expected
based on our previous planning comparative study. A critical review of all plans revealed that the results
with SW-IMRT could be improved by: (1) gaining experience and attempting to reduce SWOAR dose as
much as possible; (2) accepting a moderate shift of dose to unspeciﬁed tissues; (3) maximizing SWOAR
sparing while keeping PTV coverage exactly according to protocol. In the additional 80 patients, the mean
dose to the various SWOARs was further reduced signiﬁcantly compared to ST-IMRT. Dose reductions
with SW-IMRT were largest for patients who received neck irradiation, had a tumour located in the lar-
ynx, oropharynx, nasopharynx or oral cavity, and had <75% overlap between SWOARs and PTVs. The
mean absolute reduction in predicted physician-rated RTOG grade 2–4 swallowing dysfunction for
patients numbered 21–100 was 6.1%, ranging from 0.0% to 17.2%.
Conclusions: The beneﬁt of SW-IMRT depends signiﬁcantly on neck radiotherapy, tumour site and the
amount of overlap between SWOARs and PTVs. Optimal clinical introduction requires a detailed evalua-
tion and comparison between the standard (ST-IMRT) and new technique (SW-IMRT) in order to fully
exploit the potential beneﬁts.
 2013 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 107 (2013) 282–287We recently reported on swallowing-sparing intensity-modu-
lated radiotherapy (SW-IMRT) for head and neck cancer (HNC)
and demonstrated that the dose in swallowing organs at risk
(SWOARs) can be signiﬁcantly reduced relative to standard IMRT
(ST-IMRT), aiming at reducing the dose to the parotid glands only
[1]. By integrating the results of in-silico planning comparative
studies with multivariable predictive models for physician-rated
and patient-rated swallowing dysfunction [2], the SWOAR dose
reductions can be translated into potential clinical beneﬁts [1].
In the development phase, we found that in a group of 30 HNC pa-
tients, the average normal tissue complication probability (NTCP)
of physician-rated Radiation Therapy Oncology Group (RTOG)grade 2–4 swallowing dysfunction could be reduced from 42.3%
with ST-IMRT to 33.4% on average with SW-IMRT [1]. An impor-
tant observation was the large variation between individual pa-
tients, both with regard to the initial NTCP-values with ST-IMRT
as with regard to the reductions that could be obtained with
SW-IMRT [1,2]. Although the patient group was relatively small
and the study had a descriptive design, it seemed that tumour
location and nodal stage inﬂuenced the initial NTCP-values as well
as the potential NTCP-reductions. However, it should be noted
that the results described in that study were obtained under opti-
mal conditions, i.e., all treatment plans were thoroughly opti-
mized by a single experienced research dosimetrist (HPvdL)
without the burden and pressure of daily practice. Moreover,
treatment planning was accurately performed according to a pre-
deﬁned research protocol [1].
Table 1
Baseline patient, tumour and treatent characteristics.
n = 80 (patients #21-100)
Factors %
Gender
Male 69
Female 31
Age, years
18–65 60
>65 40
Neck radiotherapy
Local RT 9
Unilateral neck RT 21
Bilateral neck RT 70
Concomitant chemotherapy
No 66
Yes 34
Tumour location
Larynx 31
Hypopharynx 11
Oral cavity 8
Oropharynx 29
Nasopharynx 4
Other (salivary glands, skin, etc.) 17
Overlap SWOAR-PTVa
0–25% 28
26–50% 26
51–75% 25
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implemented at our department in September 2010 and by
November 2011, 100 patients had received SW-IMRT. As radiother-
apy treatment planning for SW-IMRT is more complex and time
consuming than for ST-IMRT, we felt that it was worthwhile to test
if the potential gain of SW-IMRT showed similar results as ob-
tained in the development phase when it was actually imple-
mented in routine clinical practice under less ideal circumstances
(e.g., various members of the team of dosimetrists with different
levels of skills and experience with limited time available per pa-
tient). Therefore, a prospective evaluation of the quality of the cre-
ated plans was started simultaneously with the clinical
introduction of SW-IMRT.
Our main aim was to investigate whether translation of the re-
sults of in-silico planning comparative study into real clinical prac-
tice in terms of radiotherapy treatment planning was optimal and
which factors could inﬂuence this.
The purpose of the current study was to analyse whether the
SWOARs dose reductions and subsequent estimated NTCP-reduc-
tions for physician-rated and patient-rated swallowing dysfunc-
tion were optimal when SW-IMRT was introduced into real
clinical practice. In addition, we aimed to describe the patient
and treatment related factors that inﬂuenced the results with
SW-IMRT in real clinical practice.>75% 21
T stage
T0 1
T1 14
T2 32
T3 30
T4 20
Tx 3
N stage
N0 38
N1 15
N2a 1
N2b 25
N2c 16
N3 4
Nx 1Materials and methods
Patients
The study populationwas composed of 100 consecutive patients
scheduled to receive primary (chemo)radiotherapy for HNC (Ta-
ble 1). Contrast-enhanced planning computed tomography (CT)
scans were acquired in treatment position with a slice thickness
and index of 2 mm. Radiotherapy treatment planning was per-
formed in the clinical Pinnacle3 treatment-planning system (version
8.0 h, Philips Radiation Oncology Systems, Fitchburg, WI, USA). The
adaptive convolution algorithm was used for all dose calculations.Abbreviations: PCM, pharyngeal constrictor muscle; PTV, planning target volume;
RT, radiotherapy; SWOAR, swallowing organ at risk.
a Overlap deﬁned as the proportion of the combined superior PCM and supra-
glottic larynx overlapping with any PTV.Regions of interest
The deﬁnition of the target volumes (PTV) was previously de-
scribed in more detail [3–5]. All elective and high dose PTVs were
restricted to 5 mm within the skin surface for the purpose of dose
optimization and evaluation. Different dose levels were prescribed
to the PTVs according to a simultaneous integrated boost fraction-
ation schedule, i.e., treatment plans were created with a daily high-
er dose delivered to the high dose PTVs [1]. In some patients, only a
high dose PTV was deﬁned and in some patients another total dose
was prescribed to the PTVs for medical reasons. The following
OARs were delineated: the parotid glands, spinal cord, brainstem,
optic nerves and optic chiasm. In addition, anatomical structures
found to be related to swallowing dysfunction were delineated as
well, including the superior and middle pharyngeal constrictor
muscle (PCM), the supraglottic larynx and the oesophageal inlet
muscle (EIM) [2]. Delineation was performed according to CT-
based delineation protocols for OAR deﬁnition in the head and
neck region developed at our department [6,7].IMRT treatment planning
In all patients and for all plans, direct aperture optimization-
based IMRT treatment plans were created. The technical aspects
and the dose–volume objectives of the treatment plans have been
described previously in more detail [1]. In brief, attempts were
made to obtain adequate target coverage, while limiting the dose
to structures outside the PTV for both ST-IMRT and SW-IMRT.In all patients included in this study, a two-step approach was
used. First, a ST-IMRT plan was created, aiming at optimal sparing
of the parotid glands according to routine institutional procedures
before the clinical introduction of SW-IMRT. By a trial-and-error
adaptive adjustment of the objective values and weights, the dose
plan was optimized such that a clinically acceptable plan was ob-
tained. Second, the ST-IMRT plan was saved and copied. The copy
was then used to create the SW-IMRT plan that was subsequently
used for the actual treatment of the patients. In order to minimize
the radiation dose to the SWOARs, objective values and weights
were added for the SWOARs. The doses to the SWOARs were re-
duced according to the following order of priority: (1) minimizing
mean dose to the superior PCM; (2) minimizing the mean dose to
the supraglottic larynx; (3) minimizing the mean dose to the mid-
dle PCM; and (4) minimizing the proportion of the EIM receiving
P60 Gy (EIM V60). This order of priorities was based on the out-
come of the multivariable logistic regression analysis previously
described [2]. The mean dose in the parotid glands was not allowed
to be higher with SW-IMRT than with ST-IMRT.Dose–volume data and complication probabilities
The volume in the patient receiving P95% of the dose pre-
scribed to the elective PTV and the high dose PTV were determined
284 Implementation of swallowing-sparing IMRTand relevant OAR and SWOAR dose–volume parameters were ob-
tained from corresponding dose–volume histograms (DVH). To
estimate NTCP-values for ST-IMRT and SW-IMRT with regard to
endpoints related to swallowing dysfunction, we used the equation
as previously described by Christianen et al. [2].Statistical analyses
For comparison of the DVH parameters and NTCP-values with
ST-IMRT and SW-IMRT, the mean values were analysed with the
paired-samples t-test. Linear regression analysis was performed
to identify factors that were related to the NTCP gain of SW-IMRT
relative to ST-IMRT. For comparison of the mean values in patient
sub-groups, ANOVA or independent-samples t-tests were per-
formed, depending on the number of patient sub-groups. All tests
were two-tailed, and differences were considered statistically sig-
niﬁcant when the p-value was 0.05 or less.
Results
Results for ﬁrst 20 patients
It appeared that the dose in the SWOARs in the SW-IMRT plans
for the ﬁrst 20 patients was only slightly lower than in the ST-IMRT
plans, e.g., the mean dose to the superior PCM and the supraglottic
larynx were reduced by 1.6 Gy and 2.2 Gy, on average, respectively.
The calculated mean NTCP reduction for grade 2–4 RTOG swallow-
ing dysfunction at 6 months with SW-IMRT was only 2.6%. This
gain was less than expected on the basis of the results obtained
in the development phase, in which the mean NTCP reduction
was 8.9% [1]. Moderate gains were also observed with regard to
the patient-rated complaints. The mean NTCP reduction of chock-
ing when swallowing and problems with swallowing liquids, soft
food and solid food were 0.5%, 0.6%, 0.9% and 2.4%, respectively.
In order to distinguish whether this was due to variation in patient
selection or to non-optimal treatment planning, we randomly se-
lected the SW-IMRT plans from 6 patients that were subsequently
re-planned by the same experienced research dosimetrist. After re-
planning, a marked further reduction could be obtained to the
SWOARs. This also resulted in larger reductions in the NTCP-values
for swallowing dysfunction, e.g., the mean NTCP-reduction for
RTOG grade 2–4 swallowing dysfunction with SW-IMRT increased
from 2.0% to 6.2%.Table 2
Dose–volume data and normal tissue complication probabilities.
n = 80 (patients #21-100) ST-IMRT
Integral irradiated volume (cm3)
V95% PTV1
871 (68–1911)
Parotid glands mean dose (Gy)
Ipsilateral 33.9 (0–69.9)
Contralateral 23.3 (0–53.4)
SWOAR mean dose (Gy)
Superior PCM 49.4 (1.6–70.4)
Middle PCM 53.4 (9.2–71.9)
Supraglottic larynx 55.8 (4.0–71.0)
Volume receiving P60 Gy (%)
EIM 6.8 (0–92)
NTCP swallowing dysfunction (%)
RTOG grade 2–4 29.6 (1.1–61.7)
Problems swallowing solid food 25.0 (0.5–63.3)
Problems swallowing soft food 10.3 (0.3–47.7)
Problems swallowing liquid food 6.4 (0.1–12.7)
Choking when swallowing 5.9 (0.1–36.8)
Values are means with ranges in parentheses.
Abbreviations: EIM, oesophageal inlet muscle; NTCP, normal tissue complication proba
RTOG, (physicianrated) Radiation Therapy Oncology Group; ST-IMRT, standard intensity
radiation therapy; V95% PTV1, the volume in the patient receiving 95% of the dose presIn addition, the treatment plans of all ﬁrst 20 patients were re-
viewed in the radiation oncology head and neck cancer treatment
team in order to identify the possible reasons for the non-optimal
SW-IMRT treatment plans of the ﬁrst 20 patients. Based on this re-
view, we were able to identify methods to improve the gain in the
SW-IMRT plans.
First, we observed that larger gains were obtained by more
experienced dosimetrists who had sufﬁcient time available to
maximize SWOAR sparing and really attempted to reduce the dose
in the SWOARs as much as possible. Second, we found that in order
to maximize SWOAR sparing we needed to accept a moderate shift
of dose to unspeciﬁed tissues, such as the oral cavity and the neck
muscles. Third, we found that SWOAR sparing could be improved
by allowing the PTV coverage in the vicinity of the SWOARs to be
exactly according to protocol, i.e., the SWOAR dose was decreased
until exactly 98% of the PTVs volume received 95% of the pre-
scribed dose. These ﬁndings were discussed and taken into account
in all subsequent patients.PTV coverage and irradiated volume
At least 98% of the PTVs volume received P95% of the pre-
scribed dose in almost all patients. In 9 patients, a slight under-
dosage to the PTV was accepted, because the PTV included air cav-
ities or because the dose to the brainstem or spinal cord had to be
limited. In other words, these under-dosages to the PTVs were not
related to SW-IMRT. In all cases, PTV coverage obtained with ST-
IMRT and SW-IMRT was comparable.
With SW-IMRT, the volume in the patient receivingP95% of the
dose prescribed to the largest PTV (the elective PTV in most pa-
tients but the high dose PTV in the case of a single PTV) increased
by 2.8% on average (Table 2).Dose delivered to OARs and SWOARs
All dose plans complied with the maximum allowed doses to
critical structures such as the brainstem and spinal cord. The mean
dose delivered to the parotid glands was not increased as a result
of SWOAR sparing (Table 2). The mean dose in the SWOARs was
signiﬁcantly lower with SW-IMRT. The EIM V60 was zero with both
ST-IMRT and SW-IMRT in 80% of the patients.SW-IMRT p-Value
895 (63–1911) <0.001
33.8 (0–69.9) 0.175
22.5 (0–54.2) <0.001
44.6 (1.5–69.6) <0.001
48.1 (4.2–70.3) <0.001
51.0 (2.8–70.2) <0.001
3.9 (0–58) 0.011
23.5 (0.6–59.7) <0.001
19.5 (0.2–61.4) <0.001
8.6 (0.2–45.3) <0.001
5.3 (0.1–12.0) <0.001
4.3 (0.1–16.9) <0.001
bility; PCM, pharyngeal constrictor muscle; PTV1, largest planning target volume;
modulated radiation therapy; SW-IMRT, swallowing sparing intensity modulated
cribed to PTV1 (the largest PTV).
Fig. 1. Normal tissue complication probabilities (NTCP) of physician-rated Radiation Therapy Oncology Group (RTOG) grade 2–4 swallowing dysfunction with Standard
Intensity Modulation Radiation Therapy (ST-IMRT) and Swallowing Sparing IMRT (SW-IMRT) in patients #21-100 (re-sorted by the NTCP values with ST-IMRT).
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Using the predictive models of Christianen et al. [2], we calcu-
lated the potential NTCP-reductions with SW-IMRT for patients
#21–100. For all swallowing dysfunction endpoints, the NTCP-val-
ues were signiﬁcantly lower with SW-IMRT (Table 2). The mean
NTCP-reduction for physician-rated RTOG grade 2–4 swallowing
dysfunction with SW-IMRT was 6.1% (range: 0.0–17.2%). This
reduction was 7.3% (range: 1.0–17.2%) in a subgroup of 56 patients
who received bilateral neck irradiation. In our previous study all
patients received bilateral neck irradiation and the mean NTCP-
reduction was 8.9% (range: 3.0–20.0%) [1]. The mean NTCP-reduc-
tions with SW-IMRT of patient-rated moderate-to-severe swallow-
ing complaints for patients #21–100 were: 5.5% (range 0.0–17.3%)
for solid food, 1.6% (range 0.0–6.4%) for soft food, 1.1% (range 0.0–
3.4%) for liquid food, and 1.6% (range 0.0–26.1%) for choking when
swallowing, respectively. When we limited the analysis to the sub-
group of 56 patients with bilateral neck irradiation and compared
these to the results of our previous study we found the following
NTCP reductions: 6.7% and 7.9% for solid food, 1.9% and 2.3% for
soft food, 1.3% and 1.4% for liquid food and 2.0% and 0.9% for chock-
ing when swallowing, respectively. As shown in Fig. 1, the absolute
NTCP values for ST-IMRT and SW-IMRT, as well as the NTCP-value
reductions varied widely across individual patients. The
proportions of patients and the corresponding gains that could
be obtained with SW-IMRT relative to ST-IMRT in the ﬁrst 20Fig. 2. Cumulative proportion of responders analysis, showing the proportion of
patients and corresponding potential reductions in the normal tissue complication
probability (NTCP) of physician-rated RTOG grade 2–4 swallowing dysfunction as
achieved by reducing the dose in the swallowing organs at risk (SWOARs) in three
groups of patients: (1) the ﬁrst 20 patients in the present study; (2) the subsequent
80 patients in the present study; and (3) the 30 patients in our previous study.patients, the subsequent 80 patients, and the 30 patients in our
previous study are depicted in Fig. 2.Patient, tumour and treatment characteristics
Univariable and multivariable linear regression statistics indi-
cated that neck radiotherapy (unilateral or bilateral neck irradia-
tion versus local irradiation), the degree of overlap between the
most important SWOARs (superior PCM and supraglottic larynx)
and the PTVs (<25%, 25–49%, 50–74% or P75% of these SWOARs
overlapping with any PTV), and tumour site were signiﬁcantly
associated with NTCP reductions of physician-rated RTOG grade
2–4 swallowing dysfunction with SW-IMRT. In fact, we found that
in patients who received neck irradiation, who had <75% overlap
between the SWOARs and the PTV, and who had a tumour located
in the larynx, oropharynx, oral cavity or nasopharynx, the potential
gain with regard to the NTCP of physician-rated RTOG grade 2–4
swallowing dysfunction was on average 8.6% (‘high’), while in
the other patients this was on average 3.1% (‘low’) (Table 3).Discussion
Our main purpose was to analyse whether the estimated NTCP-
reductions for different swallowing dysfunction endpoints ob-
tained with SW-IMRT in the development phase (our previous
study) were similar when introduced in routine daily practice in
the ﬁrst 100 patients actually treated with SW-IMRT (the present
study). We found that in the ﬁrst 20 patients treated with SW-
IMRT the SWOARs were spared only slightly better than with the
reference back up ST-IMRT plans made for each patient, resulting
in a potential gain with regard to the NTCP of RTOG grade 2–4
swallowing dysfunction of only 2.3%, while this was 8.9% in the
development phase [1]. We observed the same effect with regard
to the patient-rated swallowing complaints (ﬁgures not shown).
After a critical multidisciplinary evaluation of the ST-IMRT and
SW-IMRT plans of the ﬁrst 20 patients we found a number of fac-
tors that could improve the gain of SW-IMRT in clinical practice
(discussed below). These measures were taken into account in
the subsequent 80 patients and resulted in an increased gain with
SW-IMRT that were closer to the results obtained in the develop-
ment phase. In our previous study we already discussed the meth-
ods and potential gains with SW-IMRT in more detail and
compared our results with SW-IMRT to that of others [8–18].
The results of the present study demonstrate that the actual
gain with SW-IMRT depends on a number of factors. In the ﬁrst
20 patients, for example, only a minimal gain was obtained
because certain decisions were made during treatment plan
Table 3
Sub-group values for reduced swallowing dysfunction when sparing SWOARs.
Mean NTCP reduction by sparing SWOARs with SW-IMRT relative to ST-IMRT (SD) ANOVA or t-test
n = 80 n RTOG grade 2–4 p-Value
Neck radiotherapy <0.001
Local RTa 7 0.3% (0.3%)
Unilateral neck RT 17 4.3% (2.7%)
Bilateral neck RT 56 7.3% (3.9%)
Tumour location 0.001
Larynx 25 6.6% (5.2%)
Hypopharynxa 9 2.3% (0.9%)
Oral cavity 6 8.3% (3.3%)
Oropharynx 23 7.6% (3.3%)
Nasopharynx 3 8.0% (0.5%)
Salivary-skin-othera 14 3.7% (2.5%)
Overlap SWOAR-PTVb <0.001
0–25% 22 4.4% (3.3%)
26–50% 21 7.8% (4.1%)
51–75% 20 8.4% (3.0%)
>75%b 17 3.4% (3.9%)
High and low potential gain <0.001
Low potential gaina 37 3.1% (3.2%)
High potential gain 43 8.6% (2.8%)
Total 80 6.1% (4.1%)
Values are means (SD).
Abbreviations: NTCP, normal tissue complication probability; PCM, pharyngeal constrictor muscle; PTV, planning target volume; RT, radiotherapy; RTOG, (physician-rated)
Radiation Therapy Oncology Group (score); ST-IMRT, standard intensity-modulated radiotherapy; SW-IMRT, swallowing-sparing IMRT; SWOAR, swallowing organ at risk.
a Patients with local RT, a hypopharynx tumour, a tumour located outside the laryngo-pharyngeal axis or >75% overlapb were included in the low predicted gain group
based on the regression analysis.
b Overlap was deﬁned as the proportion of the combined superior PCM and supraglottic larynx overlapping with any PTV.
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re-planned patients increased the sparing of SWOARs. It appeared
that the gain of SW-IMRT was inﬂuenced by the level of experience
of the involved dosimetrist and the time allocated for treatment
planning. Physician-related factors also played an important role,
such as the willingness to accept a moderate dose shift to unspec-
iﬁed structures or a locally slightly lower, yet acceptable, dose in
the PTV as a means to provide additional SWOAR sparing. Other
factors may also have an impact. For example, different institutes
have different policies with regard to the use of speciﬁc treatment
optimization methods. In the current study the objective values
and weights were iteratively adjusted until ﬁnally a treatment plan
was obtained in which the SWOAR dose was really as low as pos-
sible. In other institutions, fully automated or class solution ap-
proaches are often used. In that case, less additional efforts are
made to spare an OAR and no further optimization is performed
as soon as an acceptable plan is obtained [19]. RT treatment plans
can fulﬁl all predeﬁned requirements, but this does not mean that
they cannot be further optimized. Other important factors that
inﬂuence the potential gain of SW-IMRT cannot be altered so eas-
ily. In our previous studies, we showed that reductions in the
NTCP-values of physician-rated grade 2–4 swallowing dysfunction
can be obtained by reducing the mean dose in the superior PCM
but also by reducing the mean dose in the supraglottic larynx
[2]. Patients with laryngeal tumours often beneﬁt from additional
sparing of the superior PCM while on the other hand patients with
oropharyngeal tumours are more likely to beneﬁt from additional
sparing of the supraglottic larynx. Tumour site also seems to have
an indirect effect on the NTCP-reductions, because tumour site
inﬂuences the degree of overlap between SWOARs and PTVs, which
in turn has an inﬂuence on the potential reductions of the NTCP
values with SW-IMRT. We found that the NTCP reductions were
strongly related to the overlap between SWOARs and PTVs. The
target volume (neck irradiation) also inﬂuenced the NTCP-reduc-
tions indirectly because patients receiving neck irradiation are
more likely to have any degree of overlap between the SWOARs
and the PTV. It appeared from the analysis that patients withintermediate overlap beneﬁtted most from SW-IMRT, whereas pa-
tients with an almost complete overlap did not gain much from
SW-IMRT, as only minor manipulation of the dose in the SWOARs
is possible in such cases.
We are currently awaiting the follow-up results of the patients
that were treated with SW-IMRT. We aim to compare the results in
these patients to the results in a comparable cohort of patients
who received ST-IMRT in the past and with whom swallowing dys-
function endpoints were prospectively scored in a similar way as in
the current group of SW-IMRT treated patients.Conclusions
The gain that can be obtained with SW-IMRT in clinical practice
with regard to the reduction of swallowing dysfunction depends
on a number of factors. Some of which can be manipulated, such
as treatment planning methodology, experience of the involved
personnel and institutional preferences, while other factors such
as the administration of neck radiotherapy, the overlap between
SWOARs and PTVs, and tumour site are patient or disease related
and may either increase or limit the options of SW-IMRT to spare
the SWOARs. Optimal clinical introduction of SW-IMRT requires
a detailed evaluation and comparison between the standard (ST-
IMRT) and new technique (SW-IMRT) in order to fully exploit the
potential beneﬁts. This study demonstrates that the introduction
of new techniques aiming at avoiding additional organs at risk by
adding new treatment planning objectives does not automatically
translate into better dose distributions when introduced into clin-
ical practice. Without optimal introduction there is no reason to
expect better clinical outcome.Conﬂict of interest
The authors state that the research presented in this manuscript
is free of conﬂicts of interest.
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